A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial

Overview of attention for article published in European Journal of Cancer (1965), April 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 3 news outlets
policy: 2 policy sources

patent: 2 patents
guideline: 2 clinical guideline sources

Readers on

mendeley: 57 Mendeley

So far, Altmetric has seen 3 policy documents that reference this research output.

Lartruvo for Advanced Soft Tissue Sarcoma – Details - Olaratumab (Lartruvo) Advanced Soft Tissue Sarcoma – Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 26 Oct 2017

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma: Committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 08 Jun 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Yondelis for Liposarcoma or Leiomyoscarcoma – Details - Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 22 Dec 2015

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.